FI771046A7 - - Google Patents

Download PDF

Info

Publication number
FI771046A7
FI771046A7 FI771046A FI771046A FI771046A7 FI 771046 A7 FI771046 A7 FI 771046A7 FI 771046 A FI771046 A FI 771046A FI 771046 A FI771046 A FI 771046A FI 771046 A7 FI771046 A7 FI 771046A7
Authority
FI
Finland
Application number
FI771046A
Other languages
Finnish (fi)
Inventor
Gordon Hanley Phillipps
George Blanch Ewan
Original Assignee
Glaxo Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Lab Ltd filed Critical Glaxo Lab Ltd
Publication of FI771046A7 publication Critical patent/FI771046A7/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J13/00Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003Androstane derivatives
    • C07J1/0011Androstane derivatives substituted in position 17 by a keto group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005Ketals
    • C07J21/008Ketals at position 17
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0011Unsubstituted amino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016Oximes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI771046A 1976-04-05 1977-04-04 FI771046A7 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB13707/76A GB1581234A (en) 1976-04-05 1976-04-05 11a - amino - 3a - hydroxysteroids

Publications (1)

Publication Number Publication Date
FI771046A7 true FI771046A7 (enExample) 1977-10-06

Family

ID=10027931

Family Applications (1)

Application Number Title Priority Date Filing Date
FI771046A FI771046A7 (enExample) 1976-04-05 1977-04-04

Country Status (19)

Country Link
JP (1) JPS52142056A (enExample)
AU (1) AU517206B2 (enExample)
BE (1) BE853227A (enExample)
DE (1) DE2715078A1 (enExample)
DK (1) DK148677A (enExample)
ES (1) ES457507A1 (enExample)
FI (1) FI771046A7 (enExample)
FR (2) FR2347382A1 (enExample)
GB (1) GB1581234A (enExample)
IE (1) IE45276B1 (enExample)
IL (1) IL51816A (enExample)
IT (1) IT1073232B (enExample)
LU (1) LU77064A1 (enExample)
NL (1) NL7703667A (enExample)
NO (1) NO771197L (enExample)
NZ (1) NZ183775A (enExample)
PL (1) PL197186A1 (enExample)
SE (1) SE7703929L (enExample)
ZA (1) ZA772029B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7288081A (en) * 1980-07-16 1982-01-21 Glaxo Group Limited 11alpha-amino-androstanes
SE8104393L (sv) * 1980-07-16 1982-01-17 Glaxo Group Ltd Llalfa-amino-androstaner
AU8095782A (en) * 1981-03-02 1982-09-09 Glaxo Group Limited 11alpha-amine-3beta-hydroxy-androstanes
ATE8641T1 (de) * 1981-05-29 1984-08-15 Glaxo Group Limited 11-alpha-amino-androstane.
DE3260539D1 (en) * 1981-05-29 1984-09-13 Glaxo Group Ltd 11-alpha-amino-androstanes
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
CZ300694A3 (en) * 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
FR2910002B1 (fr) * 2006-12-13 2009-01-30 Sanofi Aventis Sa Nouveau procede pour l'obtention diastereoselective d'une amine primaire chirale sur un steroide
JP2010037243A (ja) * 2008-08-04 2010-02-18 Mitsubishi Rayon Co Ltd ノルボルネンラクトンモノマーの製造方法
ES2738526T3 (es) 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
NZ773177A (en) 2012-01-23 2022-09-30 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
IL275725B (en) 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
AU2014256229B2 (en) 2013-04-17 2018-10-04 Sage Therapeutics, Inc. 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
RS60420B1 (sr) 2013-04-17 2020-07-31 Sage Therapeutics Inc 19-nor neuroaktivni steroidi za metode lečenja
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
PL3021852T3 (pl) * 2013-07-19 2021-07-05 Sage Therapeutics, Inc. Neuroaktywne steroidy, kompozycje i ich zastosowania
JP6466942B2 (ja) 2013-08-23 2019-02-06 セージ セラピューティクス, インコーポレイテッド 向神経活性ステロイド、組成物、及びその使用
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016061527A1 (en) 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
HUE051488T2 (hu) 2014-10-16 2021-03-01 Sage Therapeutics Inc Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére
US10774108B2 (en) 2014-11-27 2020-09-15 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
PL3250210T3 (pl) 2015-01-26 2021-07-26 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
JP6875996B2 (ja) 2015-02-20 2021-05-26 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JP7049313B2 (ja) 2016-07-11 2022-04-06 セージ セラピューティクス, インコーポレイテッド C17、c20、およびc21置換神経刺激性ステロイドおよびそれらの使用方法
ES2992037T3 (es) 2016-07-11 2024-12-05 Sage Therapeutics Inc Esteroides neuroactivos sustituidos en C7, C12 y C16 y sus procedimientos de utilización
AR114044A1 (es) * 2017-12-22 2020-07-15 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central
TWI874337B (zh) 2018-12-05 2025-03-01 美商賽吉醫療公司 神經活性類固醇及其使用方法
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
CA3143545A1 (en) * 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compounds for treating cns disorders
KR20220038681A (ko) * 2019-06-27 2022-03-29 세이지 테라퓨틱스, 인크. Cns 장애를 치료하기 위한 조성물 및 방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2982775A (en) * 1957-05-06 1961-05-02 Schering Corp 11-oximino-, amino- and acylaminosteroids

Also Published As

Publication number Publication date
ZA772029B (en) 1978-11-29
FR2485020A1 (fr) 1981-12-24
NZ183775A (en) 1979-12-11
DK148677A (da) 1977-10-06
AU2394277A (en) 1978-10-12
ES457507A1 (es) 1978-03-16
SE7703929L (sv) 1978-10-27
LU77064A1 (enExample) 1979-01-18
NO771197L (no) 1977-10-06
JPS52142056A (en) 1977-11-26
IT1073232B (it) 1985-04-13
PL197186A1 (pl) 1979-06-18
GB1581234A (en) 1980-12-10
DE2715078A1 (de) 1977-10-13
IL51816A (en) 1981-09-13
NL7703667A (nl) 1977-10-07
FR2347382B1 (enExample) 1982-01-08
IL51816A0 (en) 1977-06-30
AU517206B2 (en) 1981-07-16
IE45276L (en) 1977-10-05
BE853227A (fr) 1977-10-04
IE45276B1 (en) 1982-07-28
FR2347382A1 (fr) 1977-11-04

Similar Documents

Publication Publication Date Title
FR2347382B1 (enExample)
FR2359765B1 (enExample)
JPS5538628Y2 (enExample)
JPS52169138U (enExample)
JPS5536520Y2 (enExample)
JPS5727626Y2 (enExample)
JPS5537330B2 (enExample)
JPS5326578U (enExample)
JPS5391996U (enExample)
CS175512B1 (enExample)
JPS52108110U (enExample)
JPS5336803U (enExample)
DD127341A1 (enExample)
DD126363A1 (enExample)
CH603061A5 (enExample)
CH601522A5 (enExample)
DD125966A5 (enExample)
CH604250B5 (enExample)
CH608309A5 (enExample)
CH597972A5 (enExample)
CH597839A5 (enExample)
CH597186A5 (enExample)
CH606943A5 (enExample)
DD125798A1 (enExample)
CH598633B5 (enExample)

Legal Events

Date Code Title Description
FD Application lapsed

Owner name: GLAXO LABORATORIES LIMITED